 Home > Active Ingredient News > Blood System > FDA approved CD38 monoantigendarZALEX (daratumumab) in a joint with kafezome and dexamisson to treat recurring or refractic multiple myeloma.

FDA approved CD38 monoantigendarZALEX (daratumumab) in a joint with kafezome and dexamisson to treat recurring or refractic multiple myeloma.

 Last Update: 2020-09-22
 Source: Internet
 Author: User

Tags

blood vessel tumor

chimeric monoclonal antibody

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Danish biopharmaceutical company Genmab has announced that the U.S. Food and Drug Administration (FDA) has approved its CD38 monoantigenist DARZALEX (daratumumab) in a joint treatment with Kafezome and Desemisson (DKD) to treat adult patients with relapsed/refractic multiple myeloma after 1-3 treatments.
Van de Winkel, chief executive of Genmab, said: "We are pleased to have been approved by the FDA and daratumab is now the first CD38 antibody to be approved for use in association with Kafezome.
" about daratumab Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity with CD38 molecules, which are highly expressed on the surface of multiple myeloma cells.
daratumab triggers the body's own immune system to attack cancer cells, causing the rapid death of tumor cells.
Photo Source: About Multiple Myeloma Multiple Myeloma is an incurable blood cancer that begins in the bone marrow and is characterized by excessive proliferation of plasma cells.
multiple myeloma is the third most common blood cancer in the United States after leukemia and lymphoma.
2018, about 160,000 people worldwide were diagnosed with multiple myeloma and 106,000 died from the disease.
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.